Kara Mudd, DMSc, PA-C, a Dermatology Physician Assistant in Louisville, KY, weighs in on the recent U.S. Food and Drug Administration (FDA) approval of ruxolitinib cream (Opzelura, Incyte) for the treatment of mild-to-moderate atopic dermatitis (AD) in children as young as 2.
